SAN DIEGO – DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst expectations and provided weaker-than-expected guidance for 2025.
The company reported adjusted earnings per share of $0.45 for Q4, falling short of the $0.52 consensus estimate. Revenue came in at $1.11 billion, slightly above the $1.1 billion analysts were expecting and up 8% YoY.
For the full year 2024, DexCom’s revenue grew 11% to $4.03 billion. U.S. revenue increased 10% while international revenue rose 15%.
Looking ahead, DexCom forecast 2025 revenue of approximately $4.6 billion, below the $4.61 billion consensus. The company expects a non-GAAP gross profit margin of 64-65% and a non-GAAP operating margin of about 21%.
SAN DIEGO – DexCom , Inc. shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst expectations and provided weaker-than-expected guidance for 2025.
The company reported adjusted earnings per share of $0.45 for Q4, falling short of the $0.52 consensus estimate. Revenue came in at $1.11 billion, slightly above the $1.1 billion analysts were expecting and up 8% YoY.
For the full year 2024, DexCom’s revenue grew 11% to $4.03 billion. U.S. revenue increased 10% while international revenue rose 15%.
Looking ahead, DexCom forecast 2025 revenue of approximately $4.6 billion, below the $4.61 billion consensus. The company expects a non-GAAP gross profit margin of 64-65% and a non-GAAP operating margin of about 21%.
SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst expectations and provided weaker-than-expected guidance for 2025.
The company reported adjusted earnings per share of $0.45 for Q4, falling short of the $0.52 consensus estimate. Revenue came in at $1.11 billion, slightly above the $1.1 billion analysts were expecting and up 8% YoY.
For the full year 2024, DexCom's revenue grew 11% to $4.03 billion. U.S. revenue increased 10% while international revenue rose 15%.
Looking ahead, DexCom forecast 2025 revenue of approximately $4.6 billion, below the $4.61 billion consensus. The company expects a non-GAAP gross profit margin of 64-65% and a non-GAAP operating margin of about 21%.
